

1/13


FIGURE 1. Tetraspecific antibody structure.

FIGURE 2. Redirected PBMC cytotoxicity against astrocytoma cell line U87 that was transfected with EGFRvIII.





FIGURE 3. Redirected PBMC cytotoxicity against acute lymphoblastic leukemia cell line Kasumi-2.



4/13

FIGURE 4. Redirected PBMC cytotoxicity against astrocytoma cell line U87 that was transfected with EGFRvIII. Functional activity of different 4-1BB domains. Functional impact of PD-L1 and 4-1BB domains.




FIGURE 5. Tetraspecific antibodies binding to human ROR1 transfected CHO cells.





FIGURE 6. Tetraspecific antibodies binding to human 41BB transfected CHO cells.



7/13


FIGURE 7. Tetraspecific antibodies binding to human PD-L1 transfected CHO cells.

FIGURE 8. Tetraspecific antibodies with the binding domain 323H7 which is specific for the Ig domain of ROR1 mediated RTCC of the B-ALL cell line Kasumi2 with PBMC as effectors.




FIGURE 9. Tetraspecific antibodies with the binding domain 323H7 which is specific for the Ig domain of ROR1 mediated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RO+ memory T cells as effectors.




FIGURE 10. Tetraspecific antibodies with the binding domain 323H7 which is specific for the Ig domain of ROR1 mediated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RA+ naive T cells as effectors.




FIGURE 11. Tetraspecific antibodies with the binding domain 338H4 which is specific for the Frizzled domain of ROR1 mediated RTCC of the B-ALL cell line Kasumi2 with PBMC as effectors.




FIGURE 12. Tetraspecific antibodies with the binding domain 338H4 which is specific for the Frizzled domain of ROR1 meditated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RO+ memory T cells as effectors.




FIGURE 13. Tetraspecific antibodies with the binding domain 338H4 which is specific for the Frizzled domain of ROR1 mediated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RA+ naive T cells as effectors.

